Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 22;39(8):1190-1194.
doi: 10.1016/j.vaccine.2020.12.085. Epub 2021 Jan 22.

Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities

Benoit Hayman  1 , Alex Bowles  2 , Beth Evans  3 , Elizabeth Eyermann  4 , Lyudmila Nepomnyashchiy  5 , Sonia Pagliusi  6
Affiliations

Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities

Benoit Hayman et al. Vaccine. .

Abstract

Development of novel vaccines and improving existing vaccines is critical to addressing areas of unmet or under-addressed health needs globally and to improving existing vaccination coverage and equity. However, vaccine innovation is costly and highly complex. To understand how vaccine manufacturers from developing countries approach innovation, a survey was conducted among company members of the Developing Countries Vaccine Manufacturers Network, in collaboration with the Clinton Health Access Initiative. The survey confirmed that vaccine manufacturers from developing countries are committed to vaccine innovation: 95% of respondents have interest in pursuing vaccine innovation, with strategies targeted towards supplying to low- and middle-income countries. Key barriers to innovation were also surveyed, with respondents highlighting challenges regarding access to in-licensing or joint venture partnerships, financing, and regulatory barriers. Opportunities for innovation are also discussed.

Keywords: Developing countries; Innovation financing; Partnerships; Regulatory barriers; Vaccine development.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
DCVMN member manufacturers were asked in which of the following markets does your organization have a strategy to pursue innovation; low income, middle income, high income. In total 18 manufacturers responded to this question.
Fig. 2
Fig. 2
Proportion of emerging manufacturing engaging in licensing agreements and joint ventures.
Fig. 3
Fig. 3
Emerging manufacturers most critical barriers to investment in innovation.
See this image and copyright information in PMC

References

    1. World Economic Situation and Prospect 2019. United Nations. Available at [Accessed 10 December 2020]. https://www.un.org/development/desa/dpad/wp-content/uploads/sites/45/WES....
    1. Hayman B., Pagliusi S. Emerging vaccine manufacturers are innovating for the next decade. Vaccine X. 2020 doi: 10.1016/j.jvacx.2020.100066. - DOI - PMC - PubMed
    1. Pagliusi S., Dennehy M., Homma A., 2020. Two decades of vaccine innovations for global public good: Report of the Developing Countries’ Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil. Vaccine. DOI: 10.1016/j.vaccine.2020.05.062. - DOI - PMC - PubMed
    1. Gouglas D. et al., 2018. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health 2018 Dec; 6(12):e1386-e1396. DOI: 10.1016/S2214-109X(18)30346-2 - DOI - PMC - PubMed
    1. Azimi T. McKinsey & Company Article; 2019. Refueling the innovation engine in vaccines.https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products... Available at: [Accessed 26 October 2020]

Publication types